BNET Industries
Market Cap:$147.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Can Roche Leave Genentech Alone?
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
pfizer inc. and wyeth - All News and Analysis
Pfizer - Prempro: Kris Hundley writes
BNET
- 2009-11-20
Is Prempro, the hormone drug known to increase the risk of breast cancer, a public hazard? If a judge in Pinellas County determines that it is, hundreds of thousands of documents now under seal in lawsuits against the drug's manufacturer nationwide could be released for the public to inspect. The...
Swinging The Ax At The Drug Companies - The Atlantic Business Channel
BNET
- 2009-11-12
« The Senate Plan's Resolution Authority | Main | Does Excess Debt Lead to Bubbles? » Nov 11 2009, 11:15 am by Derek Lowe Swinging The Ax At The Drug Companies...
Pfizer Will Close Some R&D Sites, Cut Jobs
BNET
- 2009-11-09
This isn't surprising. Now that its acquistion of Wyeth is complete, the big drugmaker will "significantly reduce" R&D in various locations, and an undisclosed number of jobs will be gone (here's the press release). Various functions will be moved from Collegeville, Pa; Pearl River, NY; and St. Louis to other...
Pfizer Aiming for 30,900 Layoffs Through 2012
BNET
- 2009-11-06
Pfizer has laid off 26,300 employees since 2005, and hopes eventually to lay off a total of 30,900 through 2012, according to its 10-Q filing with the SEC. The company had several rounds of layoffs before its acquisition of Wyeth in an attempt to get $6 billion in annual savings...
Dutch pull Pfizer infant vaccine after deaths
BNET
- 2009-11-06
Dutch health authorities have yanked a batch of Pfizer's Prevnar following the deaths of three infants. Prevnar, which is known as Prevenar in Europe, is used to protect infants from certain pneumococcal bacteria that can cause meningitis and bacteremia. Pfizer acquired the drug through its recent acquisition of Wyeth. "On...
Pfizer Must Pay $75M In Damages Over Prempro
BNET
- 2009-11-05
The punitive damages will go to an Illinois woman, Connie Barton, who developed cancer after taking Prempro, Bloomberg reports, although the amount was sealed last week by a Pennsyvlania state court judge until another trial begins. A jury also awarded her $3.7 million in compensatory damages after finding the conduct...
Pfizer Won't Share Wyeth's Q3 Numbers; Layoff Announcements Due This Week
BNET
- 2009-10-21
Pfizer employees and investors were probably equally frustrated by yesterday's conference call. Management said it had axed 11,200 jobs at the company and planned to announce more layoffs this week (the merger requires 19,500 jobs to go); and despite pleas from two analysts Pfizer said it would not provide Q3...
Pfizer R&D czars big on collaboration, quiet on cuts
BNET
- 2009-10-20
One of the hottest topics in drug discovery circles right now is how the big Pfizer/Wyeth merger will play out in the companies' labs. Analysts have already been buzzing about the likelihood of billions of dollars in cuts as the two R&D operations are melded into one big outfit....
China Requires One Divestiture for Pfizer / Wyeth Merger
Seeking Alpha
- 2009-10-01
ChinaBio Today submits: The Anti-Monopoly Bureau of China’s Ministry of Commerce (MOFCOM) has given its okay to the merger between Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE). However, MOFCOM will require that Pfizer divest its swine mycoplasmal pneumonia vaccine business. Pfizer has been negotiating with the Anti-Monopoly Bureau on...
Which Pfizer / Wyeth Sites Will Shut Down?
Seeking Alpha
- 2009-09-28
Derek Lowe submits: I have no solid information on this question myself, but Eric Milgram over at Pharmaconduct is trying a wisdom-of-crowds approach. He's got a survey up of which sites people think will close, and it'll be interesting to see how well this matches up with the eventual...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
